If you follow peptide and GLP-1 drug news, you'll notice certain weeks each year produce a flood of new trial results, almost always tied to a handful of recurring medical conferences. EASD is one of the two biggest. This guide explains what it is and why it matters for how you should read the news it generates.
What EASD Is
The European Association for the Study of Diabetes (EASD) is a professional medical organization founded in the 1960s, dedicated to diabetes research, treatment, and education. Its Annual Meeting, first held decades ago and now in its sixties in terms of edition number, is one of the largest diabetes and metabolic disease conferences in the world, drawing tens of thousands of endocrinologists, researchers, and pharmaceutical company representatives. The 2026 meeting, EASD's 62nd, was held in Milan, Italy, and is a recurring reference point in this site's news coverage.
Why So Much Drug News Comes Out of It
Pharmaceutical companies developing diabetes and obesity drugs, including nearly every major GLP-1, GIP, and amylin-pathway peptide currently in development, strategically time major clinical trial readouts to coincide with EASD and its American counterpart, the American Diabetes Association's Scientific Sessions (ADA), held earlier in the year. Presenting at a major conference gives a company simultaneous access to the specialist audience most likely to prescribe or study the drug, to journalists covering the field, and often to peer-reviewed publication, since many companies coordinate a conference presentation with simultaneous publication in a major medical journal like The Lancet or the New England Journal of Medicine.
How to Read Conference-Presented Results
Data presented at a conference like EASD has usually been reviewed by the conference's own scientific committee before acceptance, which offers some quality control, but it is not the same as full peer review at a journal, and conference presentations sometimes precede the full published paper by months. When a company's press release and a conference presentation happen the same day, as is common, the numbers being reported are usually topline results chosen by the company's communications team, not necessarily the complete statistical picture a reader would get from the eventual full publication. It's also worth checking whether a given presentation reflects new data or is a fuller readout of a trial whose topline results were already announced separately, which happens frequently as companies stage the release of results from large trials.
What EASD Coverage Looks Like on This Site
Several stories this site has covered originated at or around EASD meetings, including Zealand Pharma's full Phase 2 petrelintide results published in The Lancet alongside EASD 2026 presentation, a Danish population study on GLP-1 eligibility presented at EASD 2026, Eli Lilly's ACHIEVE-4 cardiovascular results for orforglipron, and Eli Lilly's TRIUMPH-2 retatrutide data. Recognizing the EASD connection helps explain why so many major peptide drug headlines seem to cluster in the same week or two each September.
A Word on Conflicts of Interest
Virtually all clinical trial data presented at these conferences comes from industry-sponsored trials, funded and often designed by the drug's own manufacturer, with company employees frequently among the study's listed authors. That doesn't make the data invalid, large randomized controlled trials remain the strongest form of clinical evidence available, but it's a relevant piece of context, and this site's guide to conflicts of interest in peptide research goes into more detail on how to weigh sponsor involvement when reading any individual trial result.
The Bottom Line
EASD is a legitimate, long-running scientific conference, not a marketing event, but it is also the venue pharmaceutical companies deliberately choose for high-visibility drug announcements. Reading EASD-linked headlines with an understanding of that timing, and checking whether topline conference numbers have since been confirmed in full peer-reviewed publication, is a useful habit for anyone trying to separate durable clinical evidence from a single week's news cycle.